Mianserine Teva

Mianserin, the active ingredient in Mianserine Teva, is a tetracyclic antidepressant presented as an oral dosage form for oral use. It is prescribed for the treatment of major depressive disorder in adult patients. GNH USA supplies Mianserine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mianserin is a tetracyclic antidepressant that acts on depressive disorders and related conditions.

Major depressive disorder: alleviates depressive symptoms and improves mood in adults. Depressive episodes in bipolar disorder: helps control depressive phases when used under specialist supervision. Treatment‑resistant depression: may be considered when first‑line agents have been ineffective.

Mianserin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Weight gain or increased appetite - Dry mouth - Constipation - Dizziness or light‑headedness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Cardiac arrhythmias or QT prolongation - Severe hypotension - Suicidal thoughts or behavior - Hepatotoxicity

Before initiating therapy, clinicians should evaluate several safety considerations.

Monitor blood pressure: watch for orthostatic changes. Assess suicidal risk: especially during early treatment. Use caution in the elderly: increased sensitivity to sedation and falls. Avoid abrupt discontinuation: taper to reduce withdrawal symptoms. Review hepatic function: adjust if liver impairment is present. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mianserin can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents: potential serotonin syndrome. - Other antidepressants (TCAs, SNRIs): additive CNS depression. - CNS depressants (benzodiazepines, barbiturates): enhanced sedation. - QT‑prolonging drugs: increased cardiac risk.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mianserin levels. - Antihypertensives: additive hypotensive effect. - Anticholinergic medications: heightened anticholinergic burden. - Alcohol: increased sedation and dizziness. - NSAIDs: potential for gastrointestinal bleeding when combined with anticoagulants.